 Shares of Amicus Therapeutics NASDAQ:FOLD rose 0.6 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44 year over year to 0.20, which beat the estimate of 0.26.Revenue of 62,353,000 rose by 41.29 from the same period last year, which missed the estimate of 62,380,000.Outlook The upcoming fiscal years revenue expected to be between 250,000,000 and 260,000,000.Conference Call Details Date: Aug 10, 2020Time: 08:30 AMView more earnings on FOLDET Webcast URL: Action Companys 52-week high was at 16.13Companys 52-week low was at 6.25Price action over last quarter: Up 32.05Company Profile Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.See more from Benzinga Earnings Scheduled For August 10, 2020 Stocks That Hit 52-Week Highs On Wednesday Stocks That Hit 52-Week Highs On MondayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 